Today’s Research Reports on Stocks to Watch: Celldex Therapeutics and PDL BioPharma

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Celldex Therapeutics’ stock might be plummeting but Wall Street still remains adamant that the company’s stock could rise significantly in value. The company’s kiln still has metal heating up, with clinical drug trials research still ongoing. Despite the huge expenses involved in the research, analysts insist that there is still time for the market to adjust and accommodate the potential of Celldex’s stock price. Everything remained quiet regarding PDL BioPharma, with the company having a rough time maintaining stability with the stock price, and meeting the average trade volume. Here’s a closer look at the company’s performance yesterday.

RDI Initiates
Coverage:

Celldex Therapeutics,
Inc. https://ub.rdinvesting.com/news/?ticker=CLDX

PDL BioPharma Inc. https://ub.rdinvesting.com/news/?ticker=PDLI

The therapeutic company’s shares dropped 2.96% yesterday to close at $3.60. The dip however, comes amid speculations from Wall Street that the company’s stock has the potential to double up by the end of the year. Companies involved in the speculation include Idera Pharmaceuticals, Opko Health and Celldex Therapeutics. Celldex is still recovering from the failed experimental procedures involving glioblastoma vaccine Rintega late last year.

The company is currently engaged in triple-negative Breast Cancer research, with Glembatumumab vedotin (glemba) slated to be the company’s first drug. There are still other clinical trials in the pipeline, with the probability of success deemed “very likely”. This is to say that once the trials are over, the company’s stock might be the biggest beneficiary.

Access RDI’s Celldex Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CLDX

PDL BioPharma’s stock dipped 1.37% yesterday to close at $2.16. The company traded 2.4 million shares yesterday as compared to the 50 day average volume of 1.7mn shares. Pharmaceuticals remain NASDAQ’s riskiest sector, with the NASDAQ Composite Index more than doubling since 2011. Biotech companies rarely make money, and the ones that do more often than not have established brands that already enjoy commercial success. Clinical research and manufacturing costs tend to be higher than revenue, with investments helping to keep the companies afloat.

Access RDI’s PDL BioPharma Research Report at: https://ub.rdinvesting.com/news/?ticker=PDLI

Our Actionable Research on Celldex Therapeutics, Inc. (NASDAQ: CLDX) and PDL BioPharma Inc. (NASDAQ: PDLI) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458640